Cholangiocarcinoma: novel therapeutic targets

References

• Alsaleh M, Leftley Z, Barbera TA, et al. Cholangiocarcinoma: A guide for the nonspecialist. Int J Gen Med. 2019;12:13–23.
   PubMed Web of Science ®Google Scholar
• DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245:755–762.
   PubMed Web of Science ®Google Scholar
• Kirstein MM, Vogel A. Epidemiology and risk factors of cholangiocarcinoma. Visc Med. 2016;32:395–400.
   PubMed Web of Science ®Google Scholar
• Khan AS, Dageforde LA. Cholangiocarcinoma. Surg Clin North Am. 2019;99:315–335.
   PubMed Web of Science ®Google Scholar
• Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part III: liver, biliary tract, and pancreas. Gastroenterology. 2009;136:1134–1144.
   PubMed Web of Science ®Google Scholar
• Ramirez-Merino N, Aix SP, Cortes-Funes H. Chemotherapy for cholangiocarcinoma: an update. World J Gastrointest Oncol. 2013;5:171–176.
   PubMed Web of Science ®Google Scholar
• Feng X, Zheng S, Xia F, et al. Classification and management of hepatolithiasis: A high-volume, single-center’s experience. Intractable Rare Dis Res. 2012;1:151–156.
   PubMedGoogle Scholar
• Lazaridis KN, LaRusso NF. Primary sclerosing cholangitis. N Engl J Med. 2016;375:1161–1170.
   PubMed Web of Science ®Google Scholar
• Gulamhusein AF, Eaton JE, Tabibian JH, et al. Duration of inflammatory bowel disease is associated with increased risk of cholangiocarcinoma in patients with primary sclerosing cholangitis and IBD. Am J Gastroenterol. 2016;111:705–711.
   PubMed Web of Science ®Google Scholar
• Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011;54:173–184.
   PubMed Web of Science ®Google Scholar
• Walter D, Hartmann S, Waidmann O. Update on cholangiocarcinoma: potential impact of genomic studies on clinical management. Z Gastroenterol. 2017;55:575–581.
   PubMed Web of Science ®Google Scholar
• Welzel TM, Graubard BI, Zeuzem S, et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER-medicare database. Hepatology. 2011;54:463–471.
   PubMed Web of Science ®Google Scholar
• Xiong J, Lu X, Xu W, et al. Metabolic syndrome and the risk of cholangiocarcinoma: A hospital-based case-control study in China. Cancer Manag Res. 2018;10:3849–3855.
   PubMed Web of Science ®Google Scholar
• Banales JM, Cardinale V, Carpino G, et al. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European network for the study of cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13:261–280.
   PubMed Web of Science ®Google Scholar
• Jusakul A, Cutcutache I, Yong CH, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 2017;7:1116–1135.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47:1003–1010.
   PubMed Web of Science ®Google Scholar
• Golub D, Iyengar N, Dogra S, et al. Mutant isocitrate dehydrogenase inhibitors as targeted cancer therapeutics. Front Oncol. 2019;9:417.
   Web of Science ®Google Scholar
• Jain A, Borad MJ, Kelley RK, et al. Cholangiocarcinoma with FGFR genetic aberrations: A unique clinical phenotype. JCO Precis Oncol. 2018;2:1–12.
   PubMed Web of Science ®Google Scholar
• Ross JS, Wang K, Gay L, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014;19:235–242.
   PubMed Web of Science ®Google Scholar
• Sia D, Losic B, Moeini A, et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun. 2015;6:6087.
   PubMed Web of Science ®Google Scholar
• Raggi C, Fiaccadori K, Pastore M, et al. Antitumor activity of a novel fibroblast growth factor receptor inhibitor for intrahepatic cholangiocarcinoma. Am J Pathol. 2019;189:2090–2101.
   PubMed Web of Science ®Google Scholar
• Goyal L, Shi L, Liu LY, et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov. 2019;9:1064–1079.
   PubMed Web of Science ®Google Scholar
• Lamberti D, Cristinziano G, Porru M, et al. HSP90 inhibition drives degradation of FGFR2 fusion proteins: implications for treatment of cholangiocarcinoma. Hepatology. 2019;69:131–142.
   PubMed Web of Science ®Google Scholar
• Simile MM, Bagella P, Vidili G, et al. Targeted therapies in cholangiocarcinoma: emerging evidence from clinical trials. Medicina (Kaunas). 2019;55:42.
   Web of Science ®Google Scholar
• Gentilini A, Pastore M, Marra F, et al. The role of stroma in cholangiocarcinoma: the intriguing interplay between fibroblastic component, immune cell subsets and tumor epithelium. Int J Mol Sci. 2018;19:2885.
   Web of Science ®Google Scholar
• Fabris L, Perugorria MJ, Mertens J, et al. The tumour microenvironment and immune milieu of cholangiocarcinoma. Liver Int. 2019;39:63–78.
   PubMed Web of Science ®Google Scholar
• Chen Z, Guo P, Xie X, et al. The role of tumour microenvironment: A new vision for cholangiocarcinoma. J Cell Mol Med. 2019;23:59–69.
   PubMed Web of Science ®Google Scholar
• Mertens JC, Fingas CD, Christensen JD, et al. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res. 2013;73:897–907.
   PubMed Web of Science ®Google Scholar
• Ling H, Roux E, Hempel D, et al. Transforming growth factor beta neutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats. PLoS One. 2013;8:e54499.
   PubMed Web of Science ®Google Scholar
• Thongchot S, Ferraresi A, Vidoni C, et al. Resveratrol interrupts the pro-invasive communication between cancer associated fibroblasts and cholangiocarcinoma cells. Cancer Lett. 2018;430:160–171.
   PubMed Web of Science ®Google Scholar
• Vaeteewoottacharn K, Kariya R, Pothipan P, et al. Attenuation of CD47-SIRPalpha signal in cholangiocarcinoma potentiates tumor-associated macrophage-mediated phagocytosis and suppresses intrahepatic metastasis. Transl Oncol. 2019;12:217–225.
   PubMed Web of Science ®Google Scholar
• Veillette A, Chen J. SIRPalpha-CD47 immune checkpoint blockade in anticancer therapy. Trends Immunol. 2018;39:173–184.
   PubMed Web of Science ®Google Scholar
• Darvin P, Toor SM, Sasidharan Nair V, et al. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50:165.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Wang XY, Zhang Y, et al. Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8+ T-cell immune responses. Cancer Manag Res. 2018;10:4113–4123.
   PubMed Web of Science ®Google Scholar
• Lu JC, Zeng HY, Sun QM, et al. Distinct PD-L1/PD1 profiles and clinical implications in intrahepatic cholangiocarcinoma patients with different risk factors. Theranostics. 2019;9:4678–4687.
   PubMed Web of Science ®Google Scholar
• Zhou G, Sprengers D, Mancham S, et al. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules. J Hepatol. 2019;71:753–762.
   PubMed Web of Science ®Google Scholar
• Tai Y, Wang Q, Korner H, et al. Molecular mechanisms of T cells activation by dendritic cells in autoimmune diseases. Front Pharmacol. 2018;9:642.
   PubMed Web of Science ®Google Scholar
• Junking M, Grainok J, Thepmalee C, et al. Enhanced cytotoxic activity of effector T-cells against cholangiocarcinoma by dendritic cells pulsed with pooled mRNA. Tumour Biol. 2017;39:1010428317733367.
   Google Scholar
• Panya A, Thepmalee C, Sawasdee N, et al. Cytotoxic activity of effector T cells against cholangiocarcinoma is enhanced by self-differentiated monocyte-derived dendritic cells. Cancer Immunol Immunother. 2018;67:1579–1588.
   PubMed Web of Science ®Google Scholar
• Jiraviriyakul A, Songjang W, Kaewthet P, et al. Honokiol-enhanced cytotoxic T lymphocyte activity against cholangiocarcinoma cells mediated by dendritic cells pulsed with damage-associated molecular patterns. World J Gastroenterol. 2019;25:3941–3955.
   PubMed Web of Science ®Google Scholar
• Fiaschi T, Chiarugi P. Oxidative stress, tumor microenvironment, and metabolic reprogramming: a diabolic liaison. Int J Cell Biol. 2012;2012:762825.
   PubMedGoogle Scholar
• Uchida D, Takaki A, Ishikawa H, et al. Oxidative stress balance is dysregulated and represents an additional target for treating cholangiocarcinoma. Free Radic Res. 2016;50:732–743.
   PubMed Web of Science ®Google Scholar
• Reiter RJ, Mayo JC, Tan DX, et al. Melatonin as an antioxidant: under promises but over delivers. J Pineal Res. 2016;61:253–278.
   PubMed Web of Science ®Google Scholar
• Li Y, Li S, Zhou Y, et al. Melatonin for the prevention and treatment of cancer. Oncotarget. 2017;8:39896–39921.
   PubMedGoogle Scholar
• Laothong U, Hiraku Y, Oikawa S, et al. Melatonin induces apoptosis in cholangiocarcinoma cell lines by activating the reactive oxygen species-mediated mitochondrial pathway. Oncol Rep. 2015;33:1443–1449.
   PubMed Web of Science ®Google Scholar
• Laothong U, Pinlaor P, Hiraku Y, et al. Protective effect of melatonin against Opisthorchis viverrini-induced oxidative and nitrosative DNA damage and liver injury in hamsters. J Pineal Res. 2010;49:271–282.
   PubMed Web of Science ®Google Scholar
• Laothong U, Pinlaor P, Boonsiri P, et al. Melatonin inhibits cholangiocarcinoma and reduces liver injury in Opisthorchis viverrini-infected and N-nitrosodimethylamine-treated hamsters. J Pineal Res. 2013;55:257–266.
   PubMed Web of Science ®Google Scholar
• Gu FM, Gao Q, Shi GM, et al. Intratumoral IL-17+ cells and neutrophils show strong prognostic significance in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2012;19:2506–2514.
   PubMed Web of Science ®Google Scholar
• Yan C, Zhang BB, Hua H, et al. The dynamics of Treg/Th17 and the imbalance of Treg/Th17 in clonorchis sinensis-infected mice. PLoS One. 2015;10:e0143217.
   PubMed Web of Science ®Google Scholar
• Wongsena W, Charoensuk L, Dangtakot R, et al. Melatonin suppresses eosinophils and Th17 cells in hamsters treated with a combination of human liver fluke infection and a chemical carcinogen. Pharmacol Rep. 2018;70:98–105.
   PubMed Web of Science ®Google Scholar
• Rath MF, Coon SL, Amaral FG, et al. Melatonin synthesis: acetylserotonin O-methyltransferase (ASMT) is strongly expressed in a subpopulation of pinealocytes in the male rat pineal gland. Endocrinology. 2016;157:2028–2040.
   PubMed Web of Science ®Google Scholar
• Han Y, DeMorrow S, Invernizzi P, et al. Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma: its synthesis is reduced favoring cholangiocarcinoma growth. Am J Physiol Gastrointest Liver Physiol. 2011;301:G623–633.
   PubMed Web of Science ®Google Scholar
• Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br J Pharmacol. 2018;175:3190–3199.
   PubMed Web of Science ®Google Scholar
• Loeuillard E, Fischbach SR, Gores GJ, et al. Animal models of cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 2019;1865:982–992.
   PubMed Web of Science ®Google Scholar
• Cadamuro M, Brivio S, Stecca T, et al. Animal models of cholangiocarcinoma: what they teach us about the human disease. Clin Res Hepatol Gastroenterol. 2018;42:403–415.
   PubMed Web of Science ®Google Scholar
• Filipski E, Subramanian P, Carriere J, et al. Circadian disruption accelerates liver carcinogenesis in mice. Mutat Res. 2009;680:95–105.
   PubMed Web of Science ®Google Scholar
• Mteyrek A, Filipski E, Guettier C, et al. Critical cholangiocarcinogenesis control by cryptochrome clock genes. Int J Cancer. 2017;140:2473–2483.
   PubMed Web of Science ®Google Scholar
• Han Y, Meng F, Venter J, et al. miR-34a-dependent overexpression of Per1 decreases cholangiocarcinoma growth. J Hepatol. 2016;64:1295–1304.
   PubMed Web of Science ®Google Scholar
• Lv J, Liu F. The role of serotonin beyond the central nervous system during embryogenesis. Front Cell Neurosci. 2017;11:74.
   PubMed Web of Science ®Google Scholar
• Sarrouilhe D, Mesnil M. Serotonin and human cancer: a critical view. Biochimie. 2019;161:46–50.
   PubMed Web of Science ®Google Scholar
• Alpini G, Invernizzi P, Gaudio E, et al. Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Cancer Res. 2008;68:9184–9193.
   PubMed Web of Science ®Google Scholar
• Huang L, Frampton G, Rao A, et al. Monoamine oxidase A expression is suppressed in human cholangiocarcinoma via coordinated epigenetic and IL-6-driven events. Lab Invest. 2012;92:1451–1460.
   PubMed Web of Science ®Google Scholar
• Kyritsi K, Chen L, O’Brien A, et al. Modulation of the TPH1/MAO-A/5HT/5HTR2A/2B/2C axis regulates biliary proliferation and liver fibrosis during cholestasis. Hepatology. 2019.DOI: 10.1002/hep.30880
   PubMedGoogle Scholar
• Coufal M, Invernizzi P, Gaudio E, et al. Increased local dopamine secretion has growth-promoting effects in cholangiocarcinoma. Int J Cancer. 2010;126:2112–2122.
   PubMed Web of Science ®Google Scholar
• Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861–874.
   PubMed Web of Science ®Google Scholar
• Chang W, Wang Y, Li W, et al. MicroRNA-551b-3p inhibits tumour growth of human cholangiocarcinoma by targeting cyclin D1. J Cell Mol Med. 2019;23:4945–4954.
   PubMed Web of Science ®Google Scholar
• Zhang M, Shi B, Zhang K. miR-186 suppresses the progression of cholangiocarcinoma cells through inhibition of Twist1. Oncol Res. 2019;27:1061–1068.
   PubMed Web of Science ®Google Scholar
• Liao G, Liu X, Wu D, et al. MORC2 promotes cell growth and metastasis in human cholangiocarcinoma and is negatively regulated by miR-186-5p. Aging (Albany NY). 2019;11:3639–3649.
   PubMedGoogle Scholar
• Wan P, Chi X, Du Q, et al. miR-383 promotes cholangiocarcinoma cell proliferation, migration, and invasion through targeting IRF1. J Cell Biochem. 2018;119:9720–9729.
   PubMedGoogle Scholar
• Kang PC, Leng KM, Liu YP, et al. miR-191 inhibition induces apoptosis through reactivating secreted frizzled-related protein-1 in cholangiocarcinoma. Cell Physiol Biochem. 2018;49:1933–1942.
   PubMedGoogle Scholar
• Leng K, Xu Y, Kang P, et al. Akirin2 is modulated by miR-490-3p and facilitates angiogenesis in cholangiocarcinoma through the IL-6/STAT3/VEGFA signaling pathway. Cell Death Dis. 2019;10:262.
   PubMed Web of Science ®Google Scholar
• Hu ZG, Zheng CW, Su HZ, et al. MicroRNA-329-mediated PTTG1 downregulation inactivates the MAPK signaling pathway to suppress cell proliferation and tumor growth in cholangiocarcinoma. J Cell Biochem. 2019;120:9964–9978.
   PubMed Web of Science ®Google Scholar
• Wei G, Yuan Y, He X, et al. Enhanced plasma miR-142-5p promotes the progression of intrahepatic cholangiocarcinoma via targeting PTEN. Exp Ther Med. 2019;17:4190–4196.
   PubMed Web of Science ®Google Scholar
• Zhu M, Wei C, Lin J, et al. UHRF1 is regulated by miR-124-3p and promotes cell proliferation in intrahepatic cholangiocarcinoma. J Cell Physiol. 2019;234:19875–19885.
   PubMed Web of Science ®Google Scholar
• Ursu S, Majid S, Garger C, et al. Novel tumor suppressor role of miRNA-876 in cholangiocarcinoma. Oncogenesis. 2019;8:42.
   PubMed Web of Science ®Google Scholar
• Liu B, Hu Y, Qin L, et al. MicroRNA-494-dependent WDHDI inhibition suppresses epithelial-mesenchymal transition, tumor growth and metastasis in cholangiocarcinoma. Dig Liver Dis. 2019;51:397–411.
   PubMedGoogle Scholar
• Wu J, Yang B, Zhang Y, et al. miR-424-5p represses the metastasis and invasion of intrahepatic cholangiocarcinoma by targeting ARK5. Int J Biol Sci. 2019;15:1591–1599.
   PubMed Web of Science ®Google Scholar
• Xu Z, Liu G, Zhang M, et al. miR-122-5p inhibits the proliferation, invasion and growth of bile duct carcinoma cells by targeting ALDOA. Cell Physiol Biochem. 2018;48:2596–2606.
   PubMedGoogle Scholar
• Wang LJ, He CC, Sui X, et al. MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN. Oncotarget. 2015;6:5932–5946.
   PubMed Web of Science ®Google Scholar
• Peng F, Jiang J, Yu Y, et al. Direct targeting of SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma tumourigenesis and metastasis. Br J Cancer. 2013;109:3092–3104.
   PubMed Web of Science ®Google Scholar
• Sun H, Li Y, Kong H, et al. Dysregulation of KCNQ1OT1 promotes cholangiocarcinoma progression via miR-140-5p/SOX4 axis. Arch Biochem Biophys. 2018;658:7–15.
   PubMed Web of Science ®Google Scholar
• Yu J, Zhang B, Zhang H, et al. E2F1-induced upregulation of long non-coding RNA LMCD1-AS1 facilitates cholangiocarcinoma cell progression by regulating miR-345-5p/COL6A3 pathway. Biochem Biophys Res Commun. 2019;512:150–155.
   PubMed Web of Science ®Google Scholar
• Zhang B, Zhou M, Zou L, et al. Long non-coding RNA LOXL1-AS1 acts as a ceRNA for miR-324-3p to contribute to cholangiocarcinoma progression via modulation of ATP-binding cassette transporter A1. Biochem Biophys Res Commun. 2019;513:827–833.
   PubMed Web of Science ®Google Scholar
• Huang L, Jiang X, Kang P, et al. Long non-coding RNA NNT-AS1 functions as an oncogenic gene through modulating miR-485/BCL9 in cholangiocarcinoma. Cancer Manag Res. 2019;11:7739–7749.
   PubMed Web of Science ®Google Scholar
• Li Z, Li X, Du X, et al. The interaction between lncRNA SNHG1 and miR-140 in regulating growth and tumorigenesis via the TLR4/NF-kappaB Pathway in cholangiocarcinoma. Oncol Res. 2019;27:663–672.
   PubMed Web of Science ®Google Scholar
• Li O, Yi W, Yang P, et al. Long non-coding RNA UCA1 promotes proliferation and invasion of intrahepatic cholangiocarcinoma cells through targeting microRNA-122. Exp Ther Med. 2019;18:25–32.
   PubMed Web of Science ®Google Scholar
• Lin H, Yang L, Tian F, et al. Up-regulated LncRNA-ATB regulates the growth and metastasis of cholangiocarcinoma via miR-200c signals. Onco Targets Ther. 2019;12:7561–7571.
   PubMed Web of Science ®Google Scholar
• Lu WX. Long non-coding RNA MEG3 represses cholangiocarcinoma by regulating miR-361-5p/TRAF3 axis. Eur Rev Med Pharmacol Sci. 2019;23:7356–7368.
   PubMed Web of Science ®Google Scholar
• Xu Y, Yao Y, Jiang X, et al. SP1-induced upregulation of lncRNA SPRY4-IT1 exerts oncogenic properties by scaffolding EZH2/LSD1/DNMT1 and sponging miR-101-3p in cholangiocarcinoma. J Exp Clin Cancer Res. 2018;37:81.
   PubMed Web of Science ®Google Scholar
• Li Z, Jiang X, Huang L, et al. Up-regulation of ZFAS1 indicates dismal prognosis for cholangiocarcinoma and promotes proliferation and metastasis by modulating USF1 via miR-296-5p. J Cell Mol Med. 2019;23:8258–8268.
   Web of Science ®Google Scholar
• Yanez-Mo M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4:27066.
   PubMed Web of Science ®Google Scholar
• Hirsova P, Ibrahim SH, Verma VK, et al. Extracellular vesicles in liver pathobiology: small particles with big impact. Hepatology. 2016;64:2219–2233.
   PubMed Web of Science ®Google Scholar
• Sato K, Meng F, Glaser S, et al. Exosomes in liver pathology. J Hepatol. 2016;65:213–221.
   PubMed Web of Science ®Google Scholar
• Liu R, Li X, Zhu W, et al. Cholangiocyte-derived exosomal long noncoding RNA H19 promotes hepatic stellate cell activation and cholestatic liver fibrosis. Hepatology. 2019;70:1317–1335.
   PubMed Web of Science ®Google Scholar
• Sato K, Meng F, Venter J, et al. The role of the secretin/secretin receptor axis in inflammatory cholangiocyte communication via extracellular vesicles. Sci Rep. 2017;7:11183.
   PubMed Web of Science ®Google Scholar
• Haga H, Yan IK, Takahashi K, et al. Tumour cell-derived extracellular vesicles interact with mesenchymal stem cells to modulate the microenvironment and enhance cholangiocarcinoma growth. J Extracell Vesicles. 2015;4:24900.
   PubMed Web of Science ®Google Scholar
• Quante M, Tu SP, Tomita H, et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 2011;19:257–272.
   PubMed Web of Science ®Google Scholar
• Spaeth EL, Dembinski JL, Sasser AK, et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One. 2009;4:e4992.
   PubMed Web of Science ®Google Scholar
• Severino V, Dumonceau JM, Delhaye M, et al. Extracellular vesicles in bile as markers of malignant biliary stenoses. Gastroenterology. 2017;153:495–504 e498.
   PubMed Web of Science ®Google Scholar
• Arbelaiz A, Azkargorta M, Krawczyk M, et al. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2017;66:1125–1143.
   PubMed Web of Science ®Google Scholar
• Ota Y, Takahashi K, Otake S, et al. Extracellular vesicle-encapsulated miR-30e suppresses cholangiocarcinoma cell invasion and migration via inhibiting epithelial-mesenchymal transition. Oncotarget. 2018;9:16400–16417.
   PubMedGoogle Scholar
• Li L, Piontek K, Ishida M, et al. Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model. Hepatology. 2017;65:501–514.
   PubMed Web of Science ®Google Scholar
• Nakanuma Y, Sato Y, Harada K, et al. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol. 2010;2:419–427.
   PubMedGoogle Scholar
• Komuta M, Govaere O, Vandecaveye V, et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology. 2012;55:1876–1888.
   PubMed Web of Science ®Google Scholar
• Sato K, Marzioni M, Meng F, et al. Ductular reaction in liver diseases: pathological mechanisms and translational significances. Hepatology. 2019;69:420–430.
   PubMed Web of Science ®Google Scholar
• Sempoux C, Fan C, Singh P, et al. Cholangiolocellular carcinoma: an innocent-looking malignant liver tumor mimicking ductular reaction. Semin Liver Dis. 2011;31:104–110.
   PubMed Web of Science ®Google Scholar
• Yamane H, Abe T, Amano H, et al. A case of cholangiolocellular carcinoma featuring intratumoral hepatic artery penetration: A case report. Int J Surg Case Rep. 2017;35:77–81.
   PubMed Web of Science ®Google Scholar
• Fan B, Malato Y, Calvisi DF, et al. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest. 2012;122:2911–2915.
   PubMed Web of Science ®Google Scholar
• Wang J, Dong M, Xu Z, et al. Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice. Oncogene. 2018;37:3229–3242.
   PubMed Web of Science ®Google Scholar
• Wan Y, Meng F, Wu N, et al. Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells. Hepatology. 2017;66:528–541.
   PubMed Web of Science ®Google Scholar
• Wu N, Meng F, Zhou T, et al. The secretin/secretin receptor axis modulates ductular reaction and liver fibrosis through changes in transforming growth factor-beta1-mediated biliary senescence. Am J Pathol. 2018;188:2264–2280.
   PubMed Web of Science ®Google Scholar
• Wan Y, McDaniel K, Wu N, et al. Regulation of cellular senescence by miR-34a in alcoholic liver injury. Am J Pathol. 2017;187:2788–2798.
   PubMed Web of Science ®Google Scholar
• Chu H, Du F, Jiang L, et al. The efficacy of CIK-based immunotherapies for advanced solid tumors. Technol Cancer Res Treat. 2017;16:577–585.
   PubMed Web of Science ®Google Scholar
• Chamoto K, Hatae R, Honjo T. Current issues and perspectives in PD-1 blockade cancer immunotherapy. Int J Clin Oncol. 2020.DOI: 10.1007/s10147-019-01588-7
   PubMedGoogle Scholar
• Andrechak JC, Dooling LJ, Discher DE. The macrophage checkpoint CD47: sIRPalpha for recognition of ‘self’ cells: from clinical trials of blocking antibodies to mechanobiological fundamentals. Philos Trans R Soc Lond B Biol Sci. 2019;374:20180217.
   PubMed Web of Science ®Google Scholar
• Du X, Tang F, Liu M, et al. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Cell Res. 2018;28:416–432.
   PubMed Web of Science ®Google Scholar
• Sato K, Kennedy L, Liangpunsakul S, et al. Intercellular communication between hepatic cells in liver diseases. Int J Mol Sci. 2019;20:2180.
   Web of Science ®Google Scholar
• Zhou Y, Ren H, Dai B, et al. Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts. J Exp Clin Cancer Res. 2018;37:324.
   PubMed Web of Science ®Google Scholar
• Rong X, Liu J, Yao X, et al. Human bone marrow mesenchymal stem cells-derived exosomes alleviate liver fibrosis through the Wnt/beta-catenin pathway. Stem Cell Res Ther. 2019;10:98.
   PubMed Web of Science ®Google Scholar
• McDaniel K, Wu N, Zhou T, et al. Amelioration of ductular reaction by stem cell derived extracellular vesicles in MDR2 knockout mice via lethal-7 microRNA. Hepatology. 2019;69:2562–2578.
   PubMed Web of Science ®Google Scholar
• Bala S, Csak T, Momen-Heravi F, et al. Biodistribution and function of extracellular miRNA-155 in mice. Sci Rep. 2015;5:10721.
   PubMed Web of Science ®Google Scholar
• Momen-Heravi F, Bala S, Bukong T, et al. Exosome-mediated delivery of functionally active miRNA-155 inhibitor to macrophages. Nanomedicine. 2014;10:1517–1527.
   PubMed Web of Science ®Google Scholar
• Xie Y, Wang Y, Li J, et al. Cholangiocarcinoma therapy with nanoparticles that combine downregulation of MicroRNA-210 with inhibition of cancer cell invasiveness. Theranostics. 2018;8:4305–4320.
   PubMed Web of Science ®Google Scholar
• Jiang F, Ling X. The advancement of long non-coding RNAs in cholangiocarcinoma development. J Cancer. 2019;10:2407–2414.
   PubMed Web of Science ®Google Scholar
• Li J, Huang L, Li Z, et al. Functions and roles of long noncoding RNA in cholangiocarcinoma. J Cell Physiol. 2019;234:17113–17126.
   PubMed Web of Science ®Google Scholar
• Salati M, Braconi C. Noncoding RNA in cholangiocarcinoma. Semin Liver Dis. 2019;39:13–25.
   PubMed Web of Science ®Google Scholar
• Wangyang Z, Daolin J, Yi X, et al. NcRNAs and cholangiocarcinoma. J Cancer. 2018;9:100–107.
   PubMed Web of Science ®Google Scholar
• Gao L, Yang X, Zhang H, et al. Inhibition of miR-10a-5p suppresses cholangiocarcinoma cell growth through downregulation of Akt pathway. Onco Targets Ther. 2018;11:6981–6994.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yang Z, Trottier J, et al. Long noncoding RNA MEG3 induces cholestatic liver injury by interaction with PTBP1 to facilitate shp mRNA decay. Hepatology. 2017;65:604–615.
   PubMed Web of Science ®Google Scholar
• Seo W, Gao Y, He Y, et al. ALDH2 deficiency promotes alcohol-associated liver cancer by activating oncogenic pathways via oxidized DNA-enriched extracellular vesicles. J Hepatol. 2019;71:1000–1011.
   PubMed Web of Science ®Google Scholar